Stocks and Investing Stocks and Investing
Tue, January 31, 2023

Chris Shibutani Maintained (BNTX) at Hold with Decreased Target to $156 on, Jan 31st, 2023


Published on 2024-10-28 01:13:47 - WOPRAI, Chris Shibutani
  Print publication without navigation


Chris Shibutani of Goldman Sachs, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $177 to $156 on, Jan 31st, 2023.

Chris has made no other calls on BNTX in the last 4 months.



There are 4 other peers that have a rating on BNTX. Out of the 4 peers that are also analyzing BNTX, 3 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $216 on, Tuesday, January 24th, 2023
  • Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold with Decreased Target to $160 on, Friday, November 11th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $132 on, Monday, October 24th, 2022


This is the rating of the analyst that currently disagrees with Chris


  • Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $239 on, Thursday, December 15th, 2022
Contributing Sources